Evidence map›Paper›PMID 33924956›Full record

ArticleCancers2021

Genome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential.

Syuzo Kaneko, Toutai Mitsuyama, Kouya Shiraishi, Noriko Ikawa, Kanto Shozu, Ai Dozen, Hidenori Machino, Ken Asada, Masaaki Komatsu, Asako Kukita and 12 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. The Current State of Chromatin Immunoprecipitation (ChIP) from FFPE Tissues.International journal of molecular sciences · 2022
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 2 countries.

Syuzo KanekoDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0003-4558-9800
Toutai MitsuyamaArtificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan.ORCID 0000-0002-1110-6375
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0002-5821-7400
Noriko IkawaDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Kanto ShozuDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0003-4476-2202
Ai DozenDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0002-6526-8812
Hidenori MachinoDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Ken AsadaDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0003-0548-4449
Masaaki KomatsuDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.ORCID 0000-0003-0421-8085
Asako KukitaDepartment of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
Kenbun SoneDepartment of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
Hiroshi YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Noriko MotoiDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan.ORCID 0000-0001-7098-3311
Shinya HayamiSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama 641-0011, Japan.
Yutaka YoneokaDepartment of Gynecology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Tomoyasu KatoDepartment of Gynecology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Toru NatsumeMolecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, Tokyo 100-8921, Japan.
Gottfried von KeudellMemorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-7254-5374
Vassiliki SalouraCenter for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Hiroki YamaueSecond Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama 641-0011, Japan.
Ryuji HamamotoDivision of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
RIKEN Center for Advanced Intelligence Project · JPTokyo National Hospital · JPNational Cancer Centre Japan · JPThe University of Tokyo · JPWakayama Medical University · JPMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USNational Institute of Advanced Industrial Science and Technology · JPSystems Biology Institute · JP

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
The Role of WHSC1L1 in Squamous Cell Carcinoma of the Head and NeckZIABC011831 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SALOURA, VASSILIKI · 2018 to 2025
$7.6M
JSPS Grant-in-Aid for Research Activity Start-up JP16H07461JSPS Grant-in-Aid for Scientific Research Grant JP18K11542JST AIP-PRISM, Japan JPMJCR18Y4JST CREST, Japan JPMJCR1689NCI NIH HHS P30 CA008748The SGH Foundation NAThe Takeda Science Foundation NA
6 · The paper itself

Abstract

Although chromatin immunoprecipitation and next-generation sequencing (ChIP-seq) using formalin-fixed paraffin-embedded tissue (FFPE) has been reported, it remained elusive whether they retained accurate transcription factor binding. Here, we developed a method to identify the binding sites of the insulator transcription factor CTCF and the genome-wide distribution of histone modifications involved in transcriptional activation. Importantly, we provide evidence that the ChIP-seq datasets obtained from FFPE samples are similar to or even better than the data for corresponding fresh-frozen samples, indicating that FFPE samples are compatible with ChIP-seq analysis. H3K27ac ChIP-seq analyses of 69 FFPE samples using a dual-arm robot revealed that driver mutations in EGFR were distinguishable from pan-negative cases and were relatively homogeneous as a group in lung adenocarcinomas. Thus, our results demonstrate that FFPE samples are an important source for epigenomic research, enabling the study of histone modifications, nuclear chromatin structure, and clinical data.

Indexed as

ChIP-seqCTCFepigeneticsFFPEH3K27acH3K4me3robotics

Identifiers

PMID33924956
PMCPMC8125448
OpenAlexW3157891465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.